PARKHOSPS
PARK MEDI WORLD LIMITED
PARK MEDI WORLD LIMITED (PARKHOSPS) Stock Analysis & Case Study
Is PARKHOSPS a good buy? The data-driven verdict.
PARK MEDI WORLD LIMITED (PARKHOSPS) trades at ₹292,on the numbers it mixed signals, a Downstox Snapshot Score of 45/100.
On the numbers, PARK MEDI WORLD LIMITED (PARKHOSPS) mixed signals, a Downstox Snapshot Score of 45/100, weighing expensive at 45.5× earnings, ROE of 16.7%. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027-2031.
Last updated . Data snapshot for research, not investment advice.
PARKHOSPS fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
How PARKHOSPS ranks against the 2,373 companies in our screener
- PARKHOSPS's market cap of 12,623 Cr ranks in the 78th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- PARKHOSPS's book value of ₹47 ranks in the 32nd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- PARKHOSPS's promoter holding of 82.9% ranks in the top 2% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- PARKHOSPS's 3-year profit (PAT) growth of 5.0% ranks in the 35th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- PARKHOSPS's 3-year revenue growth of 10.0% ranks in the 50th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- PARKHOSPS's debt-to-equity ratio of 0.18x is lower than 65% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
Is PARKHOSPS overvalued? PARKHOSPS P/E vs peers
PARKHOSPS trades at 45.5× earnings. We don't have a verified sector peer group for this stock yet, so no sector peer median or peer comparison table is shown here. Showing one anyway would compare it against an arbitrary set of large-cap names, not real sector peers.
The bull case for PARKHOSPS
- PARKHOSPS's return on equity of 16.7% ranks in the 77th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- PARKHOSPS's return on capital employed of 19.3% ranks in the 79th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
The bear case & risks
- PARKHOSPS's P/E of 45.5x is lower than 29% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
PARKHOSPS Piotroski F-Score: 5/8, how financially strong is it?
The Piotroski F-Score grades financial strength on profitability, leverage and efficiency checks. Downstox scores the eight checks it can verify from published filings, so 8 is full marks. PARKHOSPS scores 5/8, mixed financial health.
PARKHOSPS MTF margin & leverage across 9 brokers
Margin Trading Facility lets you buy PARKHOSPS with part of the capital. Lower margin % = higher leverage. Rates compared across 9 brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| Upstox | 35.00% | 2.9× |
| Zerodha | 31.03% | 3.2× |
| Groww | 31.12% | 3.2× |
| Dhan | 31.03% | 3.2× |
| Kotak Neo | 34.97% | 2.9× |
| Paytm Money | 31.17% | 3.2× |
| PocketfulCHEAPEST | 30.84% | 3.2× |
| Anand Rathi | 31.03% | 3.2× |
| Share India | 31.10% | 3.2× |
Compare every broker on the PARKHOSPS MTF page.
About PARK MEDI WORLD LIMITED: sector, index & market-cap context
PARK MEDI WORLD LIMITED (PARKHOSPS) is a small-cap NSE-listed company, with a market capitalisation of ₹12,623 Cr. See more stocks on our screener.
How the PARKHOSPS Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of PARK MEDI WORLD LIMITED's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
PARKHOSPS analysis, FAQs
Is PARK MEDI WORLD LIMITED (PARKHOSPS) a good buy?
On the numbers, PARK MEDI WORLD LIMITED (PARKHOSPS) mixed signals, a Downstox Snapshot Score of 45/100, weighing expensive at 45.5× earnings, ROE of 16.7%. This is a data snapshot for research, not investment advice.
Is PARKHOSPS overvalued or undervalued?
PARKHOSPS trades at 45.5× earnings, expensive versus the ~22× long-run Nifty average.
What is the bull case for PARKHOSPS?
PARKHOSPS's return on equity of 16.7% ranks in the 77th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026. PARKHOSPS's return on capital employed of 19.3% ranks in the 79th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
What are the risks in PARKHOSPS?
PARKHOSPS's P/E of 45.5x is lower than 29% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.